NASDAQ:SMTI Sanara MedTech (SMTI) Stock Price, News & Analysis $23.17 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$23.40 +0.23 (+0.99%) As of 05/22/2026 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sanara MedTech Stock (NASDAQ:SMTI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sanara MedTech alerts:Sign Up Key Stats Today's Range$22.36▼$24.0050-Day Range$16.34▼$23.6452-Week Range$16.05▼$35.95Volume45,371 shsAverage Volume47,239 shsMarket Capitalization$212.24 millionP/E RatioN/ADividend YieldN/APrice Target$34.00Consensus RatingHold Company Overview Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications. With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies. The company offers a range of balloon-based dilation products, including multisinus dilation systems, as well as adjunctive instruments for tissue access and endoscopic visualization. Its ENT platform is complemented by specialized energy‐based ablation technologies and implantable devices designed to address complex nasal and ear disorders. Following its establishment through a business combination in early 2022, Sanara MedTech continues to invest in clinical studies and product enhancements aimed at broadening indications and improving procedural efficiency. The company collaborates with leading physicians and academic centers to validate its technologies and expand training programs that support adoption by surgeons worldwide. Headquartered in Irvine, California, Sanara MedTech serves markets across North America, Europe, Latin America and Asia Pacific through a combination of direct sales teams and distributor partnerships. Its leadership team comprises experienced executives and clinicians with backgrounds in medical device innovation, regulatory affairs and global commercialization. Looking forward, the company is positioned to leverage its established technology platforms to pursue growth opportunities in ENT and adjacent specialties.AI Generated. May Contain Errors. Read More Sanara MedTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreSMTI MarketRank™: Sanara MedTech scored higher than 43% of companies evaluated by MarketBeat, and ranked 614th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingSanara MedTech has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialSanara MedTech has a consensus price target of $34.00, representing about 46.7% upside from its current price of $23.17.Amount of Analyst CoverageSanara MedTech has only been the subject of 3 research reports in the past 90 days.Read more about Sanara MedTech's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sanara MedTech is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sanara MedTech is -6.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSanara MedTech has a P/B Ratio of 30.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sanara MedTech's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.54% of the float of Sanara MedTech has been sold short.Short Interest Ratio / Days to CoverSanara MedTech has a short interest ratio ("days to cover") of 5.91.Change versus previous monthShort interest in Sanara MedTech has recently decreased by 7.47%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSanara MedTech does not currently pay a dividend.Dividend GrowthSanara MedTech does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for Sanara MedTech this week, compared to 2 articles on an average week.Search Interest1 people have searched for SMTI on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sanara MedTech insiders have not sold or bought any company stock.Percentage Held by Insiders42.00% of the stock of Sanara MedTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions8.10% of the stock of Sanara MedTech is held by institutions.Read more about Sanara MedTech's insider trading history. Receive SMTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sanara MedTech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SMTI Stock News HeadlinesHow The Sanara MedTech (SMTI) Narrative Is Shifting As The US$34 Target Stays PutMay 23 at 5:23 AM | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 21, 2026 | prnewswire.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.May 25 at 1:00 AM | Brownstone Research (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 19, 2026 | globenewswire.comWall Street Zen Upgrades Sanara MedTech (NASDAQ:SMTI) to "Buy"May 16, 2026 | americanbankingnews.comSanara MedTech Inc (SMTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...May 14, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTIMay 14, 2026 | prnewswire.comSanara MedTech: From Cash Burner To Profitable GrowthMay 14, 2026 | seekingalpha.comSee More Headlines SMTI Stock Analysis - Frequently Asked Questions How have SMTI shares performed this year? Sanara MedTech's stock was trading at $23.35 at the beginning of the year. Since then, SMTI stock has decreased by 0.8% and is now trading at $23.17. How were Sanara MedTech's earnings last quarter? Sanara MedTech Inc. (NASDAQ:SMTI) posted its earnings results on Tuesday, March, 24th. The company reported $0.04 earnings per share for the quarter, missing analysts' consensus estimates of $0.11 by $0.07. The business earned $27.55 million during the quarter, compared to the consensus estimate of $27.90 million. Sanara MedTech had a negative net margin of 31.23% and a negative trailing twelve-month return on equity of 3.19%. Read the conference call transcript. Who are Sanara MedTech's major shareholders? Sanara MedTech's top institutional investors include Stonebridge Wealth Management LLC (1.49%), Royal Bank of Canada (1.43%), Renaissance Technologies LLC (0.71%) and Hsbc Holdings PLC (0.19%). View institutional ownership trends. How do I buy shares of Sanara MedTech? Shares of SMTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sanara MedTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sanara MedTech investors own include Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings3/24/2026Today5/25/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 4 days ago, SMTI's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:SMTI CIK714256 Webwww.wndm.com Phone(817) 529-2300FaxN/AEmployees60Year Founded1982Price Target and Rating Average Price Target for Sanara MedTech$34.00 High Price Target$36.00 Low Price Target$32.00 Potential Upside/Downside+46.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.77) Trailing P/E RatioN/A Forward P/E Ratio144.81 P/E GrowthN/ANet Income-$37.56 million Net Margins-31.23% Pretax Margin0.58% Return on Equity-3.19% Return on Assets-0.56% Debt Debt-to-Equity Ratio6.59 Current Ratio2.28 Quick Ratio2.05 Sales & Book Value Annual Sales$103.12 million Price / Sales2.06 Cash Flow$0.59 per share Price / Cash Flow38.97 Book Value$0.77 per share Price / Book30.09Miscellaneous Outstanding Shares9,160,000Free Float5,315,000Market Cap$212.24 million OptionableNot Optionable Beta1.16 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:SMTI) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanara MedTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanara MedTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
